The effects of corticosteroids on COPD lung macrophages: a pooled analysis

Respiratory Research

Dave Singh¹  Jonathan Plumb¹  Thomas Southworth¹  Simon Lea¹  George Booth¹  Andrew Higham¹ 

[1] Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester and University Hospital of South Manchester, NHS Foundation Trust, Manchester, UK

关键词: CXCL8;    Cytokines;    Inflammation;    Alveolar macrophages;    Corticosteroids;    COPD;   

Others  :  1233534
DOI  :  10.1186/s12931-015-0260-0

 received in 2015-01-27, accepted in 2015-08-10,  发布年份 2015

【 摘 要 】

Background

There is large variation in the therapeutic response to inhaled corticosteroids (ICS) in COPD patients. We present a pooled analysis of our previous studies investigating the effects of corticosteroids on lung macrophages, in order to robustly determine whether corticosteroid sensitivity in COPD cells is reduced compared to controls, and also to evaluate the degree of between individual variation in drug response.

Methods

Data from 20 never smokers (NS), 27 smokers (S) and 45 COPD patients was used. Lung macropahges had been stimulated with lipopolysaccharide (LPS), with or without the corticosteroid dexamethasone, and tumour necrosis factor (TNF)-α, interleukin (IL)-6 and chemokine C-X-C motif ligand (CXCL) 8 production was measured.

Results

There was no difference in the anti-inflammatory effects of corticosteroids when comparing group mean data of COPD patients versus controls. The inhibition of TNF-α and IL-6 was greater than CXCL8. The effects of corticosteroids varied considerably between subjects, particularly at lower corticosteroid concentrations.

Conclusions

We confirm that overall corticosteroid sensitivity in COPD lung macrophages is not reduced compared to controls. The varied effect of corticosteroids between subjects suggests that some individuals have an inherently poor corticosteroid response. The limited suppression of lung macrophage derived CXCL8 may promote neutrophilic inflammation in COPD.

【 授权许可】

   
2015 Higham et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2015. http://www. goldcopd.com. Accessed 10th February 2015
• [2]Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L et al.. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(26):2645-53.
• [3]Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996; 153(2):530-4.
• [4]Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax. 2002; 57(7):590-5.
• [5]Pujols L, Mullol J, Roca-Ferrer J, Torrego A, Xaubet A, Cidlowski JA et al.. Expression of glucocorticoid receptor alpha- and beta-isoforms in human cells and tissues. Am J Physiol Cell Physiol. 2002; 283(4):C1324-31.
• [6]Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005; 353(16):1711-23.
• [7]Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000; 320(7245):1297-303.
• [8]Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999; 353(9167):1819-23.
• [9]Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB et al.. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999; 340(25):1948-53.
• [10]Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW et al.. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8):775-89.
• [11]Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A et al.. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361(9356):449-56.
• [12]Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ et al.. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000; 356(9240):1480-5.
• [13]Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R et al.. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005; 60(3):193-8.
• [14]Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013; 22(1):92-100.
• [15]Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE et al.. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003; 167(1):24-31.
• [16]Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004; 200(5):689-95.
• [17]Armstrong J, Sargent C, Singh D. Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. Clin Exp Immunol. 2009; 158(1):74-83.
• [18]Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett KA et al.. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2011; 338(3):732-40.
• [19]Southworth T, Metryka A, Lea S, Farrow S, Plumb J, Singh D. IFN-gamma synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid-resistant STAT1 activation. Br J Pharmacol. 2012; 166(7):2070-83.
• [20]Plumb J, Robinson L, Lea S, Banyard A, Blaikley J, Ray D et al.. Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate. PLoS One. 2013; 8(5): Article ID e64257
• [21]Lea S, Plumb J, Metcalfe H, Spicer D, Woodman P, Fox JC et al.. The effect of PPAR-gamma ligands on in vitro and in vivo models of COPD. Eur Respir J. 2013.
• [22]Higham A, Lea S, Plumb J, Maschera B, Simpson K, Ray D et al.. The role of the liver X receptor in chronic obstructive pulmonary disease. Respir Res. 2013; 14(1):106. BioMed Central Full Text
• [23]Higham A, Lea S, Ray D, Singh D. Corticosteroid effects on COPD alveolar macrophages: dependency on cell culture methodology. J Immunol Methods. 2014; 405:144-53.
• [24]Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999; 14(5):1015-22.
• [25]de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol. 2000; 190(5):619-26.
• [26]Kaur M, Singh D. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2. J Pharmacol Exp Ther. 2013; 347(1):173-80.
• [27]Esmailpour N, Hogger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J. 1997; 10(7):1496-9.
• [28]Ratcliffe MJ, Dougall IG. Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages. BMC Pharmacol Toxicol. 2012; 13:15. BioMed Central Full Text
• [29]Lea S, Harbron C, Khan N, Booth G, Armstrong J, Singh D. Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 MAPK inhibitor. Br J Clin Pharmacol. 2014.
• [30]Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev. 1996; 17(3):245-61.
• [31]Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest. 1995; 95(6):2435-41.
• [32]Goleva E, Li LB, Eves PT, Strand MJ, Martin RJ, Leung DY. Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med. 2006; 173(6):607-16.
• [33]Milara J, Lluch J, Almudever P, Freire J, Xiaozhong Q, Cortijo J. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014; 134(2):314-22.
• [34]Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004; 4(4):372-7.
• [35]Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol. 2010; 50(1):94-100.
• [36]Mercado N, Hakim A, Kobayashi Y, Meah S, Usmani OS, Chung KF et al.. Restoration of corticosteroid sensitivity by p38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. PLoS One. 2012; 7(7): Article ID e41582
• [37]Chana KK, Fenwick PS, Nicholson AG, Barnes PJ, Donnelly LE. Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014; 133(1):207-16.e1-11.
• [38]Khorasani N, Baker J, Johnson M, Chung KF, Bhavsar PK. Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD. Int J Chron Obstruct Pulmon Dis. 2015; 10:283-91.
• [39]Knobloch J, Hag H, Jungck D, Urban K, Koch A. Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol. 2011; 109(2):138-43.
• [40]Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 3(6):435-42.